News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma
invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma. The compound shows strong activation of tumor-specific T cells in preclinical testing -